Company profile
NewAmsterdam Pharma Co N.V.
NASDAQ:NAMSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Obicetrapib | phase3 | — | 18 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (20)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06305559 | phase3 | active_not_recruiting | 2024-05-16 | 2027-11-01 | NewAmsterdam Pharma | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque |
| NCT05421078 | phase2 | completed | 2022-06-27 | 2023-03-24 | NewAmsterdam Pharma | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. |
| NCT06081166 | phase1 | completed | 2023-11-11 | 2023-12-02 | NewAmsterdam Pharma | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin |
| NCT06547359 | phase1 | completed | 2024-10-01 | 2024-11-12 | NewAmsterdam Pharma | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects |
| NCT07219602 | phase3 | recruiting | 2025-12-11 | 2028-03-01 | NewAmsterdam Pharma | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome |
FDA applications (0)
No records yet.